Chemistry:Modafinil

From HandWiki
Short description: Eugeroic medication
Modafinil
Modafinil.svg
Clinical data
Trade namesProvigil, Alertec, Modavigil, others
Other namesCRL-40476; Diphenylmethyl-sulfinylacetamide
AHFS/Drugs.comMonograph
MedlinePlusa602016
License data
Pregnancy
category
  • AU: D
Dependence
liability		Relatively low
Addiction
liability		Very low to low[1][2]
Routes of
administration		By mouth[3]
Drug classCNS stimulant
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNot determined due to its aqueous insolubility
Protein binding62.3%
MetabolismLiver (primarily via amide hydrolysis;[7] CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5 involved [8]
Elimination half-life15 hours (armodafinil),
4 hours (esmodafinil)[6]
ExcretionUrine (80%)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC15H15NO2S
Molar mass273.35 g·mol−1
3D model (JSmol)
  (verify)

Modafinil, sold under the brand name Provigil among others, is a central nervous system (CNS) stimulant medication used to treat sleepiness due to narcolepsy, shift work sleep disorder, and obstructive sleep apnea.[3][9] While it has seen off-label use as a purported cognitive enhancer to improve wakefulness in animal and human studies, the research on its effectiveness for this use is not conclusive.[10][11][12][13] Modafinil is taken by mouth.[3]

Modafinil’s side effects include headaches, anxiety, excessive adrenal gland overproduction, and nausea. Serious side effects in high doses include delusions, unfounded beliefs, paranoia, irrational thought, and transient depression, possibly due to its effects on dopamine receptors in the brain, as well as allergic reactions. The amount of medication used should be adjusted in those with kidney problems, as this medication has markedly increased side effects during renal insufficiency.[14]

It is not recommended in those with an arrhythmia, significant hypertension, or left ventricular hypertrophy.[14] Modafinil appears to work by acting on dopamine and modulating the areas of the brain involved with the sleep cycle.[3]

Originally developed in the 1970s by French neuroscientist Michel Jouvet and Lafon Laboratories, Modafinil has been prescribed in France since 1994,[15] and was approved for medical use in the United States in 1998.[9] Its legal status varies by jurisdiction; in the United States it is classified as a schedule IV controlled substance, whereas in the United Kingdom it is a prescription only medication.[14] In some countries no controls apply. It is available as a generic medication.[14] In 2020, modafinil was the 302nd most commonly prescribed medication in the United States, with just over 1,000,000 prescriptions.[16]


Usage

Uses

Medical

Modafinil is not considered[by whom?] to be a classical psychostimulant, but rather is classified[by whom?] as a eugeroic (wakefulness-promoting drug).

Sleep disorders

Modafinil is used primarily for treatment of narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea.[9][12][17][18] For obstructive sleep apnea, it is recommended that patients use continuous positive airway pressure (CPAP) appropriately before they consider starting modafinil to help with daytime sleepiness.[3] Because of the risk for development of skin or hypersensitivity reactions and serious adverse psychiatric reactions, the European Medicines Agency recommended that new patient prescriptions should be only to treat sleepiness associated with narcolepsy.[19]

Fatigue

The UK National Institute for Health and Care Excellence (NICE) and MS NGOs suggest modafinil to help with multiple sclerosis (MS) fatigue.[20][21][22]

Occupational

Modafinil was fielded to military personnel in the French Air Force, Foreign Legion, and Marine infantry during the 1st Gulf War. Being more efficient than its parent drug adrafinil, it was deemed combat-worthy by the French Ministry of Defense in 1989 and subsequently administered to personnel by their officers under the name Virgyl, in order to improve a unit's operational tempoTemplate:Jargon inline. This evaluation took place before the introduction of modafinil as medication, and the personnel involved were not informed of the product's nature.[23]

Since then, armed forces of several countries including the United States, the United Kingdom, India, and France, have expressed interest in modafinil as an alternative to amphetamine—the drug traditionally employed in combat situations or lengthy missions in which troops face sleep deprivation. The France government indicated that the Foreign Legion used modafinil during certain covert operations.[24] The United Kingdom's Ministry of Defence commissioned research into modafinil[25] from QinetiQ and spent £300,000 on one investigation.[26] In 2011, the Indian Air Force announced that modafinil was included in contingency plans.[27]

In the United States military, modafinil has been approved for use on certain United States Air Force missions, and it is being investigated for other military uses.[28] As of November 2012, modafinil is the only drug approved by the Air Force as a "go pill" for fatigue management (replacing prior use of amphetamine-based medications such as dextroamphetamine).[29] It is also used in various Special operation Forces.[citation needed]

The Canadian Medical Association Journal reports that modafinil is used by astronauts on long-term missions aboard the International Space Station. Modafinil is "available to crew to optimize performance while fatigued" and helps with the disruptions in circadian rhythms and with the reduced quality of sleep astronauts experience.[30]

Nootropic

Modafinil has been used non-medically as a "smart drug" by students, office workers, soldiers, and transhumanists.[31][32][33][34][35] Its properties of increasing mental focus and decreasing sleepiness have attracted students, professionals in the corporate and tech fields, air-force personnel, surgeons, truck drivers, and call-center workers.[36][37]

Treatment of cocaine addiction

Modafinil binds to the dopamine transporter (DAT) in an occluded conformationTemplate:Jargon inline, differently than cocaine and methylphenidate.[38][39][40] Subjects pre-treated with modafinil report experiencing less euphoria from cocaine administration.[39] Modafinil does not potentiate self-administration of cocaine in pretreated Sprague-DawleyTemplate:Jargon inline rats.[41]

The mechanism by which modafinil inhibits cocaine self-administration is likely more complex than the simple observation that modafinil occupies the DAT, as drugs like methylphenidate (another dopamine re-uptake inhibitor) fail to reduce cocaine self-administration.[38][42]

Available forms

Modafinil tablets – Modalert 200

Modafinil is available as 100 and 200 mg oral tablets.[9] It is also available as the (R)-enantiomer, armodafinil, and as a prodrug of modafinil, adrafinil.[43]

Drug tolerance

Large-scale clinical studies have not found evidence of fading impact over time (tolerance) with modafinil at therapeutic doses even with prolonged use (for forty weeks and as long as three years).[44][45][46]

Contraindications

Modafinil is contraindicated in people with known hypersensitivity to modafinil or armodafinil.[47] Modafinil is not approved for use in children for any medical conditions, in whom there is a higher risk of rare but serious dermatological toxicity.[48][49][50]

Adverse effects

The incidence of adverse effects are reported as the following: less than 10% of users report having a headache, nausea, and decreased appetite. Between 5% and 10% of users may be affected with anxiety, insomnia, dizziness, diarrhea, and rhinitis.[51] Modafinil-associated psychiatric reactions have occurred in those with and without a pre-existing psychiatric history.[52] No clinically significant changes in body weight have been observed with modafinil in clinical trials,[53] although decreased appetite and weight loss have been reported with modafinil in children and adolescents probably due to the much higher modafinil exposure in these individuals based on body weight (i.e., mg/kg doses).[54]

Rare occurrences have been reported of more serious adverse effects, including severe skin rashes and other symptoms that are probably allergy-related. From the date of initial marketing, December 1998, to January 30, 2007, the US Food and Drug Administration received six cases of severe cutaneous adverse reactions associated with modafinil, including erythema multiforme (EM), Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS syndrome, involving adult and pediatric patients. The FDA issued a relevant alert. In the same alert, the FDA also noted that angioedema and multi-organ hypersensitivity reactions have also been reported in postmarketingTemplate:Jargon inline experiences.[55] In 2007, the FDA ordered Cephalon to modify the Provigil leaflet to add in bold-face print several serious and potentially fatal conditions attributed to modafinil use, including TEN, DRESS syndrome, and SJS.

The long-term safety and effectiveness of modafinil have not been determined.[56] However, a longitudinal study in pediatric patients treated for narcolepsy for up to ten years demonstrated that modafinil and armodafinil were safe and effective, with the study concluding that use of modafinil and armodafinil significantly improved patients' ability to stay awake and did not exacerbate preexisting psychiatric conditions.[57]

Addiction and dependence

The addiction and dependence liabilities of modafinil are very low.[1][58] Modafinil shares biochemical mechanisms with addictive stimulant drugs, and some studies reported it to have similar mood-elevating properties, although to a lesser degree.[58] It is not clear whether these effects are different from those from caffeine.[59][60] Modafinil does not appear to produce euphoric effects nor deviations (i.e. abuse) from dosages assigned to the patient.[61]

Modafinil is classified by the United States FDA as a schedule IV controlled substance, a category for drugs with valid medical uses and low addiction potential.[1][62] The International Narcotics Control Board does not consider modafinil a narcotic[63] nor a psychotropic substance.[64] Modafinil may increase abstinence rates in a subgroup of cocaine addicts, and modafinil-related discontinuation adverse effects are no different from placebo.[65]

Overdose

In mice and rats, the median lethal dose (LD50) of modafinil is approximately or slightly greater than 1250 mg/kg. Oral LD50 values for rats range from 1000 to 3400 mg/kg. Intravenous LD50 for dogs is 300 mg/kg. Clinical trials on humans involving taking up to 1200 mg/day for 7–21 days. Known incidents of acute one-time overdoses up to 4500 mg did not appear to cause life-threatening effects, although a number of adverse experiences were observed, including excitation or agitation, insomnia, anxiety, irritability, aggressiveness, confusion, nervousness, tremor, palpitations, sleep disturbances, nausea, and diarrhea.[9] As of 2004, the FDA is not aware of any fatal overdoses involving modafinil alone (as opposed to multiple drugs including modafinil).[9]

Interactions

Taking modafinil along with opioids such as methadone, hydrocodone, oxycodone, or fentanyl may result in a drop in opioid plasma concentrations, because modafinil is an inducer of the CYP3A4 enzymes. If the patient is not monitored closely, reduced efficacy or withdrawal symptoms can occur.[66] Modafinil may have an adverse effect on hormonal contraceptives for up to a month after discontinuation.[67] In a 2006 study, a single dose of modafinil 200 mg caused a decrease in blood prolactin levels, although it did not affect human growth hormone or thyroid-stimulating hormone.[68][69] Since modafinil can induce the activity of the CYP3A4 enzyme involved in cortisol clearance,[70] modafinil may reduce the bioavailability of hydrocortisone. Therefore, it may be necessary to adjust the steroid substitution dose in subjects receiving CYP3A4-metabolism-inducing drugs such as modafinil.[71] Modafinil is a weak to moderate inducer of CYP3A4.[72][73]

Pharmacology

Pharmacodynamics

Modafinil activity profile
Site Potency Type Species Refs
NET >10 μM
>92 μM
35.6 μM
136 μM		 Ki
Ki
IC50a
IC50a		 Human
Rat
Human
Rat		 [74][75]
[74]
[76][77]
[74]
SERT >10 μM
46.6 μM
>500 μM
>50 μM		 Ki
Ki
IC50a
IC50a		 Human
Rat
Human
Rat		 [74][75]
[74]
[76][77]
[74]
D2 >10 μM
16 nMb
120 nMb		 Ki
Ki
EC50a		 Human
Rat
Rat		 [74]
[78]
[78]
Footnotes: a = Functional activity, not binding inhibition. b = Armodafinil at D2High. Notes: No activity at a variety of other assessed targets.[74]

Mechanism of action

(As of 2017) the precise therapeutic mechanism of action of modafinil for narcolepsy and sleep-wake disorders remains unknown.[79][80] Modafinil acts as an atypical, selective, and weak dopamine reuptake inhibitor and indirectly activates the release of orexin neuropeptides and histamine from the lateral hypothalamus and tuberomammillary nucleus, all of which may contribute to heightened arousal.[79][80][81][82]

Dopamine reuptake inhibitor

Modafinil elevates dopamine levels in the hypothalamus in animals.[83] The locus of the monoamine action of modafinil was also studied, with effects identified on dopamine in the striatum and, in particular, nucleus accumbens,[84][85] norepinephrine in the hypothalamus and ventrolateral preoptic nucleus,[86][87] and serotonin in the amygdala and frontal cortex.[88] Modafinil was screened at a large panel of receptors and transporters in an attempt to elucidate its pharmacology.[74] Of the sites tested, it was found to significantly affect only the dopamine transporter (DAT), acting as a dopamine reuptake inhibitor (DRI) with an IC50 value of 4 μM.[74] Modafinil binds to the same site on the DAT as cocaine, but in a different manner.[89][90] Modafinil increases locomotor activity and extracellular dopamine concentrations in animals in a manner similar to the selective DRI vanoxerine (GBR-12909),[91] and also inhibits methamphetamine-induced dopamine release (a common property of DRIs, since DAT transport facilitates methamphetamine's access to its intracellular targets). As such, "modafinil is an exceptionally weak, but apparently very selective, [DAT] inhibitor".[92] In addition to animal research, a human positron emission tomography (PET) imaging study found that 200 mg and 300 mg doses of modafinil resulted in DAT occupancy of 51.4% and 56.9%, respectively, which is "close to that of methylphenidate".[93] Another human PET imaging study similarly found that modafinil occupied the DAT and also determined that it significantly elevated extracellular levels of dopamine in the brain, including in the nucleus accumbens.[94]

Modafinil has been described as an "atypical" DAT inhibitor, and shows a profile of effects that is very different from those of other dopaminergic stimulants.[95][96] For instance, modafinil produces wakefulness reportedly without the need for compensatory sleep, and shows relatively low, if any, potential for abuse.[97][92][95][96] Aside from modafinil, other atypical DAT inhibitors include vanoxerine and benztropine, which have a relatively low abuse potential similar to modafinil.[95] These drugs appear to interact with the DAT in a distinct way from "conventional" DAT blockers such as cocaine and methylphenidate.[90][95] Analogues of modafinil with modafinil-like versus cocaine-like dopamine reuptake inhibition and effects have been synthesized.[98]

Dopamine transporter-independent actions

Evidence against the hypothesis that modafinil exerts its effects by acting as a DRI is that tyrosine hydroxylase inhibitors (which deplete dopamine) fail to block the effects of modafinil in animals.[99] Modafinil fails to reverse reserpine-induced akinesia, whereas dextroamphetamine, a dopamine releasing agent (DRA), is able to do so.[100] One of the first published structure–activity relationship studies of modafinil found that DAT inhibition did not correlate with wakefulness-promoting effects in animals among modafinil analogues.[101] A variety of analogues without significant DAT inhibition still produce wakefulness-promoting effects.[101] "[The] neurochemical effects [of modafinil] and anatomical pattern of brain area activation differ from typical psychostimulants and are consistent with its beneficial effects on cognitive performance processes such as attention, learning, and memory".[97] Another study found that modafinil-induced increased locomotor activity in animals was dependent on histamine release and could be abolished by depletion of neuronal histamine, whereas those of methylphenidate were not and could not be.[83] Taken together, although it is established that modafinil is a clinically significant DRI, its full pharmacology remains unclear, and may include DAT-independent actions.[89][97] One such action may be activation of the orexin system.[82][89][97]

There is nonetheless evidence that modafinil produces at least some of its wakefulness-promoting effects by acting as a DRI, or at least via activation of the dopaminergic system. In support of the hypothesis that modafinil acts as a dopaminergic agent, its wakefulness-promoting effects are abolished in DAT knockout mice (although DAT knockout mice show D1 and D2 receptor and norepinephrine compensatory abnormalities that might confound this finding), reduced by both D1 and D2 receptor antagonists (although conflicting reports exist),[100] and completely blocked by simultaneous inactivation of both D1 and D2 receptors.[92] Modafinil shows full stimulus generalizationTemplate:Jargon inline to other DAT inhibitors including cocaine, methylphenidate, and vanoxerine, and discriminationTemplate:Jargon inline is blocked by administration of both ecopipam (SCH-39166), a D1 receptor antagonist, and haloperidol, a D2 receptor antagonist.[96] Partial substitutionTemplate:Jargon inline was seen with the DRA dextroamphetamine and the D2 receptor agonist PNU-91356A, as well as with nicotine (which indirectly elevates dopamine levels through activation of nicotinic acetylcholine receptors).[96]

Modafinil may have an additional mechanism of action: Both modafinil and its metabolite, modafinil sulfone, possess anticonvulsant properties in animals, and modafinil sulfone is nearly as potent as modafinil in producing this effect.[102] However, modafinil sulfone lacks wakefulness-promoting effects in animals, indicating that a distinct mechanism may be at play in the anticonvulsant effects of both compounds.[102]

Dopamine D2 receptor partial agonist

Armodafinil, the (R)-enantiomer of modafinil, acts as a D2High receptor partial agonist,[103] with a Ki of 16 nM, an intrinsic activity of 48%, and an EC50 of 120 nM, in rat striatal tissue.[78] Esmodafinil, the (S)-enantiomer of modafinil, is inactive with respect to the D2 receptor.[78] Modafinil directly inhibits the firing of midbrain dopaminergic neurons in the ventral tegmental area and substantia nigra of rats via activation of D2 receptors.[104] However, modafinil seems not to interact with the human D2 receptor (Ki = >10 μM).[74]

Dampening of amygdala activity

There is some mouse and human evidence (via direct fMRI observation and anxiety questionnaires) to suggest that modafinil may reduce amygdala activity.[105][106] The amygdala is involved in fear processing, and the dampening of its activity reduces perceptions of fear in response to environmental stress.[107] One study documented a statistically significant reduction in fear response among human subjects given 100 mg of modafinil daily for 7 days.[105] However, another study investigating the acute effects of modafinil on fear processing reported an increase in amygdala responses to fearful faces after administration of 600 mg of modafinil in human subjects.[108] Modafinil's dose dependent effects on fear processing may exhibit a Yerkes–Dodson relationship.

Other actions

One in vitro study predicts that modafinil may induce the cytochrome P450 enzymes CYP1A2, CYP3A4, and CYP2B6, as well as may inhibit CYP2C9 and CYP2C19.[8] However, other in-vitro studies find no significant inhibition of CYP2C9.[7][109] Modafinil may induce P-glycoprotein, which may affect drugs transported by P-glycoprotein, such as digoxin.[110]

Pharmacokinetics

Cmax (peak levels) occurs approximately 2 to 3 hours after modafanil administration. Food slows absorption of modafanil, but does not affect the total AUC. In vitro measurements indicate that 60% of modafinil is bound to plasma proteins at clinical concentrations of the drug. This percentage changes very little when the concentration of modafinil is varied.[111]

Renal excretion of unchanged modafinil accounts for less than 10% of an oral dose.[clarification needed][7] The two major circulating metabolites of modafinil are modafinil acid (CRL-40467) and modafinil sulfone (CRL-41056).[112][7] Both of these metabolites have been described as inactive,[113] and neither appear to contribute to the wakefulness-promoting effects of modafinil.[112][7][114] However, modafinil sulfone does appear to possess anticonvulsant effects, a property that it shares with modafinil.[102]

Elimination half-life is in the range of 10 to 12 hours, subject to differences in CYP genotypes, liver function, and renal function. Modafinil is metabolized in the liver, and its inactive metabolite is excreted in the urine. Urinary excretion of the unchanged drug ranges from 0% to as high as 18.7%, depending on various factors.[111][clarification needed]

Chemistry

Enantiomers

Armodafinil ((R)-(−)-modafinil)
Esmodafinil ((S)-(+)-modafinil)

Modafinil is a racemic mixture of two enantiomers, armodafinil ((R)-modafinil) and esmodafinil ((S)-modafinil).[77][115]

Detection in body fluids

Modafinil and/or its major metabolite, modafinil acid, may be quantified in plasma, serum, or urine to monitor dosage in those receiving the drug therapeutically, to confirm a diagnosis of poisoning in hospitalized patients, or to assist in the forensic investigation of a vehicular traffic violation. Instrumental techniques involving gas or liquid chromatography are usually employed for these purposes.[116][117] As of 2011, modafinil is not tested for by common drug screens (except for anti-doping screens) and is unlikely to cause false positives for other chemically unrelated drugs such as substituted amphetamines.[77]

Reagent testing can screen for the presence of modafinil in samples.

Colors produced by modafinil with various reagents
RC Marquis Reagent Liebermann Froehde
Modafinil Yellow/Orange > Brown[118][119] Darkening Orange[118] Deep orange/red[119]

Structural analogues

Many derivatives and structural analogues of modafinil have been synthesized and studied.[98][120][90] Examples include adrafinil, CE-123, fladrafinil (CRL-40941; fluorafinil), flmodafinil (CRL-40940; bisfluoromodafinil, lauflumide), and modafinil sulfone (CRL-41056).[121]

History

Modafinil was originally developed in France by Neurophysiology professor Michel Jouvet and Lafon Laboratories. Modafinil was among a series of benzhydryl sulfinyl compounds invented in the 1970s, including adrafinil, which was first offered as an experimental treatment for narcolepsy in France in 1986.[15] Modafinil is the primary metabolite of adrafinil, lacking the polar -OH group on its terminal amide,[122] and has similar activity to the parent drug but is much more widely used.[citation needed] It has been prescribed in France since 1994 under the name Modiodal,[15] and in the US since 1998 as Provigil.

In 1998, modafinil was approved by the U.S. Food and Drug Administration[123] for the treatment of narcolepsy and in 2003 for shift work sleep disorder and obstructive sleep apnea/hypopnea[124] even though caffeine and amphetamine were shown to be more wakefulness promoting on the Stanford Sleepiness Test Score than modafinil.[80]

Modafinil was approved for use in the UK in December 2002. Modafinil is marketed in the United States by Cephalon, who originally leased the rights from Lafon, but eventually purchased the company in 2001.

Cephalon began to market armodafinil, the (R)-enantiomer of modafinil, in the United States in 2007. After protracted patent litigation and negotiations (see below), generic versions of modafinil became available in the US in 2012.

Patent protection and litigation

U.S. Patent 4,927,855 was issued to Laboratoire L. Lafon on May 22, 1990, covering the chemical compound modafinil. After receiving an interim term extension of 1066 days and pediatric exclusivity of six months, the patent expired on October 22, 2010.

On October 6, 1994, Cephalon filed an additional patent, covering modafinil in the form of particles of defined size. That patent, U.S. Patent 5,618,845 was issued on April 8, 1997. It was reissued in 2002 as RE 37,516, which surrendered the 5618845 patent. With pediatric exclusivity, this patent expired on April 6, 2015.[125][126]

On December 24, 2002, anticipating the expiration of exclusive marketing rights, generic drug manufacturers Mylan, Teva, Barr, and Ranbaxy applied to the FDA to market a generic form of modafinil.[127] At least one withdrew its application after early opposition by Cephalon based on the RE 37,516 patent. There is uncertainty about whether a particle size patent is sufficient protection against the manufacture of generics: including whether modafinil may be modified or manufactured to avoid the granularities specified in the new Cephalon patent, and whether patenting particle size is invalid because particles of appropriate sizes are likely to be obvious to practitioners skilled in the art. However, under United States patent law, a patent is entitled to a legal presumption of validity, meaning that in order to invalidate the patent, much more than "pertinent questions" of this sort are required.

On October 31, 2011, U.S. Reissue Patent No. RE 37,516 was declared invalid and unenforceable.[128] The District Court for the Eastern District of Pennsylvania ruled that RE 37,516 was invalid because it: (1) was on sale more than one year prior to the date of the application in violation of 35 U.S.C. section 102(b); (2) was actually invented by someone else (the French company Laboratoire L. Lafon); (3) was obvious at the time the invention was made to a person having ordinary skill in the art under 35 U.S.C. section 103(a); and (4) failed the written description requirement of 35 U.S.C. section 112.[129] The patent was also found to be unenforceable due to Cephalon's inequitable conduct during patent prosecution.[129]

Cephalon made an agreement with four major generics manufacturers Teva, Barr Pharmaceuticals, Ranbaxy Laboratories, and Watson Pharmaceuticals between 2005 and 2006 to delay sales of generic modafinil in the US until April 2012 by these companies in exchange for upfront and royalty payments.[130] Litigation arising from these agreements is still pending, including an FTC suit filed in April 2008.[131]

Apotex received regulatory approval in Canada despite a suit from Cephalon's marketing partner in Canada, Shire Pharmaceuticals.[132][133] Cephalon sued Apotex in the US to prevent it from releasing a genericized armodafinil (Nuvigil).[134] Cephalon's 2011 attempt to merge with Teva was approved by the FTC under a number of conditions, including granting generic US rights to another company;[135] ultimately, Par Pharmaceutical acquired the US modafinil rights as well as some others.[136]

In the United Kingdom, Mylan Inc. received regulatory approval to sell generic modafinil produced by Orchid in January 2010; Cephalon sued to prevent sale, but lost the patent trial.[137]

Society and culture

Brand names

Modafinil is sold under a variety of brand names worldwide, including Alertec, Alertex, Altasomil, Aspendos, Forcilin, Intensit, Mentix, Modafinil, Modafinilo, Modalert, Modanil, Modasomil, Modvigil, Modiodal, Modiwake, Movigil, Provigil, Resotyl, Stavigile, Vigia, Vigicer, Vigil, Vigimax, Wakelert, and Zalux.[138]

Legal status

Australia

In Australia, modafinil is considered to be a Schedule 4 prescription-only medicine or prescription animal remedy.[139] Schedule 4 is defined as "Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription."

Canada

In Canada , modafinil is not listed in the Controlled Drugs and Substances Act, but it is a Schedule F prescription drug,[140] so it is subject to seizure by Canada Border Services Agency.

China

In mainland China , modafinil is strictly controlled like other stimulants such as amphetamines and methylphenidate. It is classified as Class I psychotropic drug,[141] meaning that only doctors who have the right to prescribe narcotics and Class I psychotropic drugs (usually through special examination) can prescribe it, for no more than three-day use (or seven-day use for control/extend-release products).[142] The first and only modafinil product was approved in November 2017,[143] but its marketing status in mainland China is still unknown[to whom?].

Japan

In Japan , modafinil is Schedule I psychotropic drug.[144][145] Cephalon licensed Alfresa Corporation to produce, and Mitsubishi Tanabe Pharma to sell modafinil products under the trade name Modiodal in Japan.[146] There have been arrests of people who imported modafinil for personal use.[147][148]

Romania

Modafinil is considered a stimulant doping agent and as such is prohibited in sports competitions. It is in the same category as steroids.[149] Due to laws passed in 2022, import into the country or selling is considered a felony and can be punished with jail time from three to seven years.[150] Simple possession for personal use is punished with a fine and confiscation.

Russia

In Russia modafinil is Schedule II controlled substance like cocaine and morphine. Possession of few modafinil pills can lead to three to ten years imprisonment.[151]

Sweden

In Sweden, modafinil is classified as a schedule IV substance; possession is illegal without prescription.[152]

United States

Modafinil is (As of 2005) classified as a Schedule IV controlled substance under United States federal law. It is illegal to import by anyone other than a DEA-registered importer without a prescription.[153] The Clinton administration issued regulations in 64 FR 4050 effective January 27, 1999, based upon a recommendation of the administration's Assistant Secretary for Health.[154]

A person may legally bring modafinil into the United States in person from a foreign country, provided that he or she has a prescription for it, and the drug is properly declared at the border crossing. U.S. residents are limited to 50 dosage units (e.g., pills).[155] Under the US Pure Food and Drug Act, drug companies are not allowed to market their drugs for off-label uses (treatments of conditions other than those officially approved by the FDA);[156] Cephalon was reprimanded in 2002 by the FDA because its promotional materials were found to be "false, lacking in fair balance, or otherwise misleading".[157] Cephalon pleaded guilty to a criminal violation and paid several fines, including $50 million and $425 million fines to the U.S. government in 2008.[158][159]

Other countries

The following countries do not classify modafinil as a controlled substance:

  • In Finland, modafinil is a prescription drug but not listed as a controlled substance.[160]
  • In Denmark, modafinil is a prescription drug but not listed as a controlled substance.[161]
  • Mexico (Not listed as a controlled substance, in the National Health Law. Can be purchased in pharmacies without prescription.)[162]
  • South Africa Schedule V[163]
  • United Kingdom (not listed in Misuse of Drugs Act so possession is not illegal, but a prescription is required) [164]

Sports use and issues

The regulation of modafinil as a doping agent has been controversial in the sporting world, with high-profile cases attracting press coverage since several prominent American athletes tested positive for the substance. Some athletes who used modafinil protested that the drug was not on the prohibited list at the time of their offenses.[165] However, the World Anti-Doping Agency (WADA) maintains that modafinil was related to already-banned substances. The Agency added modafinil to its list of prohibited substances on August 3, 2004, ten days before the start of the 2004 Summer Olympics.

Several athletes (such as sprinter Kelli White in 2004, cyclist David Clinger[166] and basketball player Diana Taurasi[167] in 2010, and rower Timothy Grant in 2015[168]) were accused of using modafinil as a performance-enhancing doping agent. Taurasi and another player—Monique Coker, tested at the same lab—were later cleared.[169] The BALCO scandal brought to light an unsubstantiated (but widely published) account of Major League Baseball's all-time leading home-run hitter Barry Bonds' supplemental chemical regimen that included modafinil in addition to anabolic steroids and human growth hormone.[170] Modafinil prolongs exercise time to exhaustion while performing at 85% of VO2max and also reduces the perception of effort required to maintain this threshold.[171]

Research

Psychiatric conditions

Major depression

Modafinil has been studied in the treatment of major depressive disorder.[172][173][174][175][176][177][178][179] In a 2021 systematic review and meta-analysis of randomized controlled trials of psychostimulants for depression, modafinil and other stimulants such as methylphenidate and amphetamines improved depression in traditional meta-analysis.[179] However, when subjected to network meta-analysis, modafinil and most other stimulants did not significantly improve depression, with only methylphenidate remaining effective.[179] Modafinil and other stimulants likewise did not improve quality of life in the meta-analysis, although there was evidence for reduced fatigue and sleepiness with modafinil and other stimulants.[179] While significant effectiveness of modafinil for depression has been reported,[173][175][178] reviews and meta-analyses note that the effectiveness of modafinil for depression is limited, the quality of available evidence is low, and more research is needed.[172][174][176][179]

Bipolar depression

Modafinil and armodafinil have been repurposed as adjunctive treatments for acute depression in people with bipolar disorder.[103] A 2021 meta-analysis found that add-on modafinil and armodafinil were more effective than placebo on response to treatment, clinical remission, and reduction in depressive symptoms, with only minor side effects, but the effect sizes are small and the quality of evidence is therefore low, limiting the clinical relevance of the evidence.[103] Very low rates of mood switchTemplate:Jargon inline have been observed with modafinil and armodafinil in bipolar disorder.[175]

Attention deficit hyperactivity disorder

Modafinil was reported to be effective in the treatment of attention deficit hyperactivity disorder (ADHD), with significantly less abuse potential than conventional psychostimulants like methylphenidate and amphetamines.[180][181] In the United States, an application to market modafinil for pediatric ADHD was submitted to the FDA.[54] However, approval was denied due to concerns about rare but serious dermatological toxicity (Stevens–Johnson syndrome).[54] Modafinil may be used off-label in the US to treat ADHD in both children and adults.[182][180][183] However, evidence of modafinil for treatment of adult ADHD is mixed, and a 2016 systematic review of alternative drug therapies for adult ADHD could not recommend its use in this context.[184] In a large phase 3 clinical trial of modafinil for adult ADHD, modafinil was not effective in improving symptoms and there was a high rate of side effects (86%) and discontinuation (47%).[185] The poor tolerability of modafinil in this study was possibly due to the use of excessively high doses (210–510 mg/day).[185]

Substance dependence

Modafinil was studied for the treatment of stimulant dependence.[182][54][186][97][65][98][187]

Schizophrenia

Modafinil and armodafinil were studied as a complement to antipsychotic medications in the treatment of schizophrenia. They showed no effect on positive symptoms or cognitive performance.[188][189] A 2015 meta-analysis found that modafinil and armodafinil may slightly reduce negative symptoms in people with acute schizophrenia, though they do not appear useful for people with the condition who are stable, with high negative symptom scores.[189] Among medications demonstrated to be effective for reducing negative symptoms in combination with anti-psychotics, modafinil and armodafinil are among the smallest effect sizes.[190]

Cognitive enhancement

A 2015 review of clinical studies of possible nootropic effects in healthy people found: "...whilst most studies employing basic testing paradigms show that modafinil intake enhances executive function, only half show improvements in attention and learning and memory, and a few even report impairments in divergent creative thinking. In contrast, when more complex assessments are used, modafinil appears to consistently engender enhancement of attention, executive functions, and learning. Importantly, we did not observe any preponderances for side effects or mood changes."[12] A 2019 review of studies of a single-dose of modafinil on mental function in healthy, non-sleep deprived people found a statistically significant but small effect and concluded that the drug has limited usefulness as a cognitive enhancer in non-sleep deprived persons.[11] A 2020 review of the cognitive enhancing potential of methylphenidate, d-amphetamine, and modafinil in healthy individuals across various domains found that modafinil has a small, positive effect on memory updating.[191]

Modafinil has been used off-label in trials with people with post-chemotherapy cognitive impairment, also known as "chemobrain", but a 2011 review found that it was no better than placebo.[192]

Post-anesthesia sedation

General anesthesia is required for many surgeries, but may cause lingering fatigue, sedation, and/or drowsiness after surgery that lasts for hours to days. In outpatient settings in which patients are discharged home after surgery, this sedation, fatigue, and occasional dizziness is problematic. Modafinil has been tested and reported to be effective in one small (N=34) double-blind randomized controlled trial for this use.[182]

Fatigue

Modafinil was studied for use in multiple sclerosis-associated fatigue, but the resulting evidence was weak and inconclusive.[193][194][195]

Postural orthostatic tachycardia syndrome

caution should be exercised in patients who have narcolepsy in comorbidity with postural orthostatic tachycardia syndrome (POTS). Therefore, there are {{clarify|text=potential|date=March 2023 reat narcolepsy. Centrally acting stimulants like modafinil first-line drugs for narcolepsy. However, modafinil stimulation increases POTS-related autonomic dysfunction and results in tachycardia/arrhythmia side effects in patients with cardiovascular risk factors. Sodium oxybate, a metabolite of GABA, is an alternative drug for stimulant-intolerant patients. Therefore, </ref>

References

  1. ↑ 1.0 1.1 1.2 "A practical guide to the therapy of narcolepsy and hypersomnia syndromes". Neurotherapeutics 9 (4): 739–752. October 2012. doi:10.1007/s13311-012-0150-9. PMID 23065655. "Because of the relatively low risk of addiction, modafinil can be more easily prescribed in patients without a clear, biochemically defined central hypersomnia syndrome, and is also easier to stop, if needed. It is also a schedule IV compound.". 
  2. ↑ "A rare case modafinil dependence". Journal of Pharmacology & Pharmacotherapeutics (J Pharmacol Pharmacotherapy) 6 (1): 49–50. 2015. doi:10.4103/0976-500X.149149. PMID 25709356. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 "Modafinil Monograph for Professionals". American Society of Health-System Pharmacists. https://www.drugs.com/monograph/modafinil.html. 
  4. ↑ "Modafinil Product information". April 25, 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63139. 
  5. ↑ "Provigil- modafinil tablet". November 30, 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16c26ad-7bc2-d155-3a5d-da83ad6492c8. 
  6. ↑ "Nuvigil- armodafinil tablet". November 30, 2018. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d878aed0-ddbf-8fa1-abf7-d3e480260845. 
  7. ↑ 7.0 7.1 7.2 7.3 7.4 "Clinical pharmacokinetic profile of modafinil". Clinical Pharmacokinetics 42 (2): 123–137. 2003. doi:10.2165/00003088-200342020-00002. PMID 12537513. 
  8. ↑ 8.0 8.1 "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil". Drug Metabolism and Disposition 28 (6): 664–671. June 2000. PMID 10820139. 
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 "Provigil Prescribing Information". Teva Pharmaceuticals USA, Inc.. January 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf. 
  10. ↑ "A systematic review of modafinil: potential clinical uses and mechanisms of action.". Journal of Clinical Psychiatry 67 (4): 554–566. April 2006. doi:10.4088/JCP.v67n0406. PMID 16669720. https://www.psychiatrist.com/jcp/depression/systematic-review-modafinil-potential-clinical-uses/. 
  11. ↑ 11.0 11.1 "The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology 39 (5): 455–461. 2019. doi:10.1097/JCP.0000000000001085. PMID 31433334. 
  12. ↑ 12.0 12.1 12.2 "Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review". European Neuropsychopharmacology 25 (11): 1865–1881. November 2015. doi:10.1016/j.euroneuro.2015.07.028. PMID 26381811. 
  13. ↑ Rethinking Cognitive Enhancement. Oxford University Press. 2017. p. 116. ISBN 9780198727392. https://books.google.com/books?id=aAIXDgAAQBAJ&pg=PA116. 
  14. ↑ 14.0 14.1 14.2 14.3 BNF 74 (74 ed.). Pharmaceutical Press. September 2017. p. 468. ISBN 978-0857112989. 
  15. ↑ 15.0 15.1 15.2 "Smart drugs et nootropiques". Socio-anthropologie (43): 97–110. 2021. doi:10.4000/socio-anthropologie.8393. ISSN 1276-8707. 
  16. ↑ "Modafinil - Drug Usage Statistics". https://clincalc.com/DrugStats/Drugs/Modafinil. 
  17. ↑ "Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report". Sleep 30 (11): 1445–1459. November 2007. doi:10.1093/sleep/30.11.1445. PMID 18041479. 
  18. ↑ "Circadian rhythm abnormalities". Continuum 19 (1 Sleep Disorders): 132–147. February 2013. doi:10.1212/01.CON.0000427209.21177.aa. PMID 23385698. 
  19. ↑ European Medicines Agency, January 27, 2011, Questions and answers on the review of medicines containing Modafinil
  20. ↑ "Overview | Multiple sclerosis in adults: Management | Guidance |". The National Institute for Health and Care Excellence (NICE). June 22, 2022. https://www.nice.org.uk/guidance/ng220. 
  21. ↑ "Modafinil (Provigil) | MS Trust". https://mstrust.org.uk/a-z/modafinil-provigil. 
  22. ↑ "Provigil". National Multiple Sclerosis Society. https://www.nationalmssociety.org/Treating-MS/Medications/Provigil. 
  23. ↑ "Les cobayes de la guerre du Golfe". Le Monde.fr. December 18, 2005. https://www.lemonde.fr/societe/article/2005/12/18/les-cobayes-de-la-guerre-du-golfe_722462_3224.html. 
  24. ↑ "It's Wake-Up Time". Wired. November 1, 2003. ISSN 1059-1028. https://www.wired.com/2003/11/sleep/. Retrieved May 23, 2019. 
  25. ↑ "BBC report on MoD research into modafinil". BBC News. October 26, 2006. http://news.bbc.co.uk/1/hi/uk_politics/6083840.stm. 
  26. ↑ "MoD's secret pep pill to keep forces awake". The Scotsman. February 27, 2005. http://www.scotsman.com/news/health/mod-s-secret-pep-pill-to-keep-forces-awake-1-1387967. 
  27. ↑ "Pilot pill project". News – City. PuneMirror. February 16, 2011. http://www.punemirror.in/article/2/201102162011021606331644587714a65/Pilot-pill-project.html. 
  28. ↑ "Modafinil and management of aircrew fatigue". United States Department of the Air Force. December 1, 2003. http://www.hep.afrl.af.mil/HEPF/Policy/modafinil.pdf. 
  29. ↑ "Air Force Special Operations Command Instruction 48–101". November 30, 2012. http://static.e-publishing.af.mil/production/1/afsoc/publication/afi11-202v3_afsocsup/afi11-202v3_afsocsup.pdf. "(sects. 1.7.4), U.S. Air Force Special Operations Command" 
  30. ↑ "The space-flight environment: the International Space Station and beyond". CMAJ 180 (12): 1216–1220. June 2009. doi:10.1503/cmaj.081125. PMID 19487390. 
  31. ↑ "Super Soldiers? Military Drug New Rage". ABC News. December 7, 2008. https://abcnews.go.com/Technology/Health/story?id=3408266. 
  32. ↑ "Like It or Not, "Smart Drugs" Are Coming to the Office". Harvard Business Review. May 2015. https://hbr.org/2016/05/like-it-or-not-smart-drugs-are-coming-to-the-office. 
  33. ↑ "Students used to take drugs to get high. Now they take them to get higher grades". The Guardian. February 14, 2015. https://www.theguardian.com/society/2015/feb/15/students-smart-drugs-higher-grades-adderall-modafinil. 
  34. ↑ "Brain Gain". The New Yorker. http://www.newyorker.com/magazine/2009/04/27/brain-gain. Retrieved April 9, 2017. 
  35. ↑ "Medikamente: 100 Milligramm Arbeitswut". Die Zeit. August 21, 2003. http://www.zeit.de/2003/35/M-Modafinil/komplettansicht. 
  36. ↑ "Stimulant use among prehospital emergency care personnel in Gauteng Province, South Africa". South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde 111 (6): 587–590. May 2021. doi:10.7196/SAMJ.2021.v111i6.15465. PMID 34382572. 
  37. ↑ "Professors are taking the same 'smart drugs' as students to keep up with workloads" (in en). May 30, 2017. https://www.independent.co.uk/news/education/education-news/professor-smart-drugs-modafinil-noopept-students-workloads-university-research-teaching-academic-cambridge-a7763041.html. 
  38. ↑ 38.0 38.1 "The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors". PLOS ONE 6 (10): e25790. October 17, 2011. doi:10.1371/journal.pone.0025790. PMID 22043293. Bibcode: 2011PLoSO...625790S. 
  39. ↑ 39.0 39.1 "Modafinil-cocaine interactions: clinical implications" (in English). Biological Psychiatry 72 (5): 346. September 2012. doi:10.1016/j.biopsych.2012.07.004. PMID 22872012. 
  40. ↑ "Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons". Neuropharmacology 123: 410–419. September 2017. doi:10.1016/j.neuropharm.2017.06.016. PMID 28625719. 
  41. ↑ "Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions". Neuropsychopharmacology 45 (9): 1518–1526. August 2020. doi:10.1038/s41386-020-0680-5. PMID 32340023. 
  42. ↑ "Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence". Substance Abuse and Rehabilitation 6: 61–74. December 31, 2015. doi:10.2147/SAR.S50807. PMID 26124696. 
  43. ↑ "Modafinil: Development and Use of the Compound". Sleep Medicine. New York, NY: Springer New York. 2015. pp. 541–544. doi:10.1007/978-1-4939-2089-1_61. ISBN 978-1-4939-2088-4. 
  44. ↑ "Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice". Journal of Affective Disorders 95 (1–3): 111–114. October 2006. doi:10.1016/j.jad.2006.01.010. PMID 16737742. 
  45. ↑ "Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy". Sleep Medicine 1 (3): 231–243. July 2000. doi:10.1016/s1389-9457(00)00031-9. PMID 10828434. 
  46. ↑ "Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group". Annals of Neurology 43 (1): 88–97. January 1998. doi:10.1002/ana.410430115. PMID 9450772. 
  47. ↑ "FDA data on Modafinil". 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020717s030s034s036lbl.pdf. 
  48. ↑ "FDA Provigil Drug Safety Data". January 2015. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf. 
  49. ↑ "Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects". Substance Abuse 41 (2): 155–173. 2020. doi:10.1080/08897077.2019.1700584. PMID 31951804. 
  50. ↑ "A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents". Neuropsychiatric Disease and Treatment 3 (3): 293–301. June 2007. PMID 19300563. 
  51. ↑ "Modafinil". StatPearls. Treasure Island (FL): StatPearls Publishing. February 2022. https://www.ncbi.nlm.nih.gov/books/NBK531476/. 
  52. ↑ "Australian Adverse Drug Reactions Bulletin 2008" (etext). Australian Adverse Drug Reactions Bulletin. December 1, 2008. https://www.tga.gov.au/publication-issue/australian-adverse-drug-reactions-bulletin-vol-27-no-6#a2. 
  53. ↑ "Provigil". Medication Guide. Cephalon, Inc.. November 1, 2010. http://provigil.com/media/PDFs/medication_guide.pdf. 
  54. ↑ 54.0 54.1 54.2 54.3 "Approved and investigational uses of modafinil : an evidence-based review". Drugs 68 (13): 1803–1839. 2008. doi:10.2165/00003495-200868130-00003. PMID 18729534. 
  55. ↑ "Modafinil (marketed as Provigil): Serious Skin Reactions". Food and Drug Administration. 2007. https://www.fda.gov/cder/dsn/2007_fall/postmarketing.htm#modafinil. 
  56. ↑ "Pharmacotherapy for excessive daytime sleepiness". Sleep Medicine Reviews 8 (5): 339–354. October 2004. doi:10.1016/j.smrv.2004.03.002. PMID 15336235. 
  57. ↑ "0954 Long-Term Use of Modafinil and Armodafinil in Pediatric Patients with Narcolepsy" (in en). Sleep 40 (suppl_1): A354–A355. April 28, 2017. doi:10.1093/sleepj/zsx050.953. ISSN 0161-8105. https://academic.oup.com/sleep/article/40/suppl_1/A354/3782402. 
  58. ↑ 58.0 58.1 "Provigil: Prescribing information". Cephalon, Inc. January 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf. 
  59. ↑ "Practical use and risk of modafinil, a novel waking drug". Environmental Health and Toxicology 27: e2012007. February 22, 2012. doi:10.5620/eht.2012.27.e2012007. PMID 22375280. 
  60. ↑ "Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo" (in en). European Psychiatry 8 (4): 201–208. 1993. doi:10.1017/S0924933800002923. ISSN 0924-9338. https://www.cambridge.org/core/journals/european-psychiatry/article/subjective-effects-of-modafinil-a-new-central-adrenergic-stimulant-in-healthy-volunteers-a-comparison-with-amphetamine-caffeine-and-placebo/93F7E13895D08AD480940C7B5664D84B. 
  61. ↑ "Does modafinil produce euphoria?". The American Journal of Psychiatry 163 (6): 1109. June 2006. doi:10.1176/ajp.2006.163.6.1109. PMID 16741217. 
  62. ↑ "A systematic review of modafinil: Potential clinical uses and mechanisms of action". The Journal of Clinical Psychiatry 67 (4): 554–566. April 2006. doi:10.4088/jcp.v67n0406. PMID 16669720. http://pdfs.semanticscholar.org/227a/c1127322026353e2c1b61eabf23b2d0b9040.pdf. 
  63. ↑ International Narcotics Control Board (July 2020), Yellow List: List of Narcotic Drugs Under International Control, In accordance with the Single Convention on Narcotic Drugs, 1961 [Protocol of March 25, 1972, amending the Single Convention on Narcotic Drugs, 1961] (59th ed.), Yellow List PDF, https://www.incb.org/incb/en/narcotic-drugs/Yellowlist/yellow-list.html 
  64. ↑ International Narcotics Control Board (July 2020), Green List: List of Psychotropic Substances Under International Control, In accordance with Convention psychotropic substances of 1971 (31st ed.), United Nations Publications, Green List PDF, https://www.incb.org/incb/en/psychotropics/toolkit.html 
  65. ↑ 65.0 65.1 "Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis". Substance Use & Misuse 52 (10): 1292–1306. August 2017. doi:10.1080/10826084.2016.1276597. PMID 28350194. 
  66. ↑ "Modafinil drug interactions". https://www.drugs.com/drug-interactions/modafinil-index.html. 
  67. ↑ "National Institutes Drug Information: Modafinil". NIH. July 1, 2005. https://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a602016.html. 
  68. ↑ "Modafinil: a review of neurochemical actions and effects on cognition". Neuropsychopharmacology (Springer Science and Business Media LLC) 33 (7): 1477–1502. June 2008. doi:10.1038/sj.npp.1301534. PMID 17712350. 
  69. ↑ "Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers". Journal of Psychopharmacology (SAGE Publications) 20 (6): 756–770. November 2006. doi:10.1177/0269881106060770. PMID 16401653. 
  70. ↑ "Regioselective hydroxylation of steroid hormones by human cytochromes P450". Drug Metabolism Reviews (Informa UK Limited) 47 (2): 89–110. May 2015. doi:10.3109/03602532.2015.1011658. PMID 25678418. 
  71. ↑ "[Adrenal crisis associated with modafinil use]" (in es). Medicina 81 (5): 846–849. 2021. PMID 34633961. 
  72. ↑ "Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers". FDA. May 26, 2021. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. 
  73. ↑ "Cytochrome P450 3A (including 3A4) inhibitors and inducers". UpToDate. https://www.uptodate.com/contents/image?imageKey=CARD%2F76992. 
  74. ↑ 74.00 74.01 74.02 74.03 74.04 74.05 74.06 74.07 74.08 74.09 74.10 Cite error: Invalid <ref> tag; no text was provided for refs named pmid19197004
  75. ↑ 75.0 75.1 Cite error: Invalid <ref> tag; no text was provided for refs named pmid34423920
  76. ↑ 76.0 76.1 Cite error: Invalid <ref> tag; no text was provided for refs named pmid29115823
  77. ↑ 77.0 77.1 77.2 77.3 "R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse". Biological Psychiatry 72 (5): 405–413. September 2012. doi:10.1016/j.biopsych.2012.03.022. PMID 22537794. 
  78. ↑ 78.0 78.1 78.2 78.3 "Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil". Synapse 63 (8): 698–704. August 2009. doi:10.1002/syn.20647. PMID 19391150. 
  79. ↑ 79.0 79.1 "Modafinil". Prescriber's Guide: Stahl's Essential Psychopharmacology (6th ed.). Cambridge, United Kingdom: Cambridge University Press. March 2017. pp. 491–495. ISBN 9781108228749. 
  80. ↑ 80.0 80.1 80.2 "Mechanisms of modafinil: A review of current research". Neuropsychiatric Disease and Treatment 3 (3): 349–364. June 2007. PMID 19300566. 
  81. ↑ "Action of modafinil through histaminergic and orexinergic neurons". Sleep Hormones. Vitamins & Hormones. 89. 2012. pp. 259–78. doi:10.1016/B978-0-12-394623-2.00014-7. ISBN 9780123946232. 
  82. ↑ 82.0 82.1 "Modafinil and orexin system: interactions and medico-legal considerations". Frontiers in Bioscience 24 (3): 564–575. January 2019. doi:10.2741/4736. PMID 30468674. 
  83. ↑ 83.0 83.1 "Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats". European Journal of Pharmacology 578 (2–3): 209–215. January 2008. doi:10.1016/j.ejphar.2007.09.009. PMID 17920581. 
  84. ↑ "Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants". European Journal of Pharmacology 568 (1–3): 112–123. July 2007. doi:10.1016/j.ejphar.2007.03.044. PMID 17477916. 
  85. ↑ "Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats". Behavioural Brain Research 176 (2): 353–357. January 2007. doi:10.1016/j.bbr.2006.10.016. PMID 17098298. 
  86. ↑ "Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats". NeuroReport 12 (16): 3533–3537. November 2001. doi:10.1097/00001756-200111160-00032. PMID 11733706. 
  87. ↑ "Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study". Sleep 27 (1): 19–25. February 2004. PMID 14998233. 
  88. ↑ "Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression". Journal of Neuroscience Research 68 (1): 107–112. April 2002. doi:10.1002/jnr.10196. PMID 11933055. 
  89. ↑ 89.0 89.1 89.2 "Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation". Neuroscience 252: 118–124. November 2013. doi:10.1016/j.neuroscience.2013.07.071. PMID 23933217. 
  90. ↑ 90.0 90.1 90.2 "Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinylacetamide (modafinil) analogues"]. Journal of Medicinal Chemistry 57 (3): 1000–1013. February 2014. doi:10.1021/jm401754x. PMID 24494745. 
  91. ↑ "Dopamine D1 and D2 receptor family contributions to modafinil-induced wakefulness". The Journal of Neuroscience 29 (9): 2663–2665. March 2009. doi:10.1523/JNEUROSCI.5843-08.2009. PMID 19261860. 
  92. ↑ 92.0 92.1 92.2 "Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions". Frontiers in Neurology 4: 139. October 2013. doi:10.3389/fneur.2013.00139. PMID 24109471. 
  93. ↑ "In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [¹⁸F]FE-PE2I". The International Journal of Neuropsychopharmacology 17 (5): 697–703. May 2014. doi:10.1017/S1461145713001612. PMID 24451483. 
  94. ↑ "Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications". JAMA 301 (11): 1148–1154. March 2009. doi:10.1001/jama.2009.351. PMID 19293415. 
  95. ↑ 95.0 95.1 95.2 95.3 "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence 147: 1–19. February 2015. doi:10.1016/j.drugalcdep.2014.12.005. PMID 25548026. 
  96. ↑ 96.0 96.1 96.2 96.3 "Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats". Psychopharmacology 232 (24): 4411–4419. December 2015. doi:10.1007/s00213-015-4065-0. PMID 26374456. 
  97. ↑ 97.0 97.1 97.2 97.3 97.4 "The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders". Psychopharmacology 229 (3): 415–434. October 2013. doi:10.1007/s00213-013-3232-4. PMID 23934211. 
  98. ↑ 98.0 98.1 98.2 "Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder". Current Opinion in Pharmacology 56: 13–21. February 2021. doi:10.1016/j.coph.2020.07.007. PMID 32927246. 
  99. ↑ The Neuroscience of Sleep. Academic Press. May 22, 2010. pp. 191–. ISBN 978-0-12-375722-7. https://books.google.com/books?id=E15ToNvBLcQC&pg=PA191. 
  100. ↑ 100.0 100.1 "Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice". European Neuropsychopharmacology 5 (4): 509–514. December 1995. doi:10.1016/0924-977x(95)00041-m. PMID 8998404. 
  101. ↑ 101.0 101.1 "Wake promoting agents: search for next generation modafinil, lessons learned: part III". Bioorganic & Medicinal Chemistry Letters 22 (11): 3751–3753. June 2012. doi:10.1016/j.bmcl.2012.04.031. PMID 22546675. 
  102. ↑ 102.0 102.1 102.2 "Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity". Neurochemical Research 29 (8): 1481–1486. August 2004. doi:10.1023/b:nere.0000029559.20581.1a. PMID 15260124. 
  103. ↑ 103.0 103.1 103.2 "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research 143: 230–238. November 2021. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. 
  104. ↑ "Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors". Neuropharmacology 52 (2): 626–633. February 2007. doi:10.1016/j.neuropharm.2006.09.005. PMID 17070873. 
  105. ↑ 105.0 105.1 "Modulatory effects of modafinil on neural circuits regulating emotion and cognition". Neuropsychopharmacology 35 (10): 2101–2109. September 2010. doi:10.1038/npp.2010.83. PMID 20555311. 
  106. ↑ "Behavioral effects of modafinil in marmoset monkeys". Psychopharmacology 185 (4): 433–440. May 2006. doi:10.1007/s00213-006-0340-4. PMID 16550386. 
  107. ↑ ePainAssist Team (March 20, 2018). "What Happens If Amygdala Is Damaged?" (in en-US). https://www.epainassist.com/brain/what-happens-if-amygdala-is-damaged. 
  108. ↑ "APA PsycNet". https://psycnet.apa.org/record/2018-15751-005. 
  109. ↑ "Effect of Modafinil at Steady State on the Single-Dose Pharmacokinetic Profile of Warfarin in Healthy Volunteers". The Journal of Clinical Pharmacology 42 (12): 205–214. March 8, 2013. doi:10.1177/00912700222011120. PMID 11831544. https://accp1.onlinelibrary.wiley.com/doi/abs/10.1177/00912700222011120. 
  110. ↑ "Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein". European Journal of Pharmacology 578 (2–3): 148–158. January 2008. doi:10.1016/j.ejphar.2007.09.035. PMID 17963743. 
  111. ↑ 111.0 111.1 Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill. 2001. p. 1984. ISBN 978-0-07-135469-1. 
  112. ↑ 112.0 112.1 "Determination of modafinil in plasma and urine by reversed phase high-performance liquid-chromatography". Journal of Pharmaceutical and Biomedical Analysis 37 (3): 475–479. March 2005. doi:10.1016/j.jpba.2004.11.014. PMID 15740906. https://zenodo.org/record/1259161. 
  113. ↑ "Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers". Journal of Clinical Pharmacology 38 (10): 971–978. October 1998. doi:10.1002/j.1552-4604.1998.tb04395.x. PMID 9807980. 
  114. ↑ "Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers". Clinical Pharmacology and Therapeutics 71 (1): 46–56. January 2002. doi:10.1067/mcp.2002.121217. PMID 11823757. 
  115. ↑ "Armodafinil-induced wakefulness in animals with ventrolateral preoptic lesions". Nature and Science of Sleep 6: 57–63. 2014. doi:10.2147/NSS.S53132. PMID 24833927. 
  116. ↑ "Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers". Journal of Clinical Pharmacology 38 (3): 276–282. March 1998. doi:10.1002/j.1552-4604.1998.tb04425.x. PMID 9549666. 
  117. ↑ Disposition of Toxic Drugs and Chemicals in Man. Foster City, CA: Biomedical Publications. 2008. pp. 1152–1153. ISBN 978-0-9626523-7-0. 
  118. ↑ 118.0 118.1 "Analytical Profiles for Five "Designer" Tryptamines" (PDF). Microgram Journal 3 (1–2): 54–68. 2005. http://www.erowid.org/library/periodicals/microgram/microgram_journal_2005-1.pdf#page=54. 
  119. ↑ 119.0 119.1 "Modafinil reaction with the Froehde reagent and others". Reagent Tests UK. December 13, 2015. http://www.reagent-tests.uk/blog/modafinil-reaction-with-the-froehde-reagent-and-others/. 
  120. ↑ "Efficient synthesis and biological evaluation of two modafinil analogues". Bioorganic & Medicinal Chemistry 16 (23): 9904–9910. December 2008. doi:10.1016/j.bmc.2008.10.027. PMID 18954992. 
  121. ↑ "The Psychonauts' World of Cognitive Enhancers". Frontiers in Psychiatry 11: 546796. 2020. doi:10.3389/fpsyt.2020.546796. PMID 33024436. 
  122. ↑ "Modafinil: past, present and future". Expert Review of Neurotherapeutics 2 (4): 449–457. July 2002. doi:10.1586/14737175.2.4.449. PMID 19810941. 
  123. ↑ "Use of wake-up drug modafinil takes off, spurred by untested uses – Los Angeles Times". LA Times. May 2, 2013. http://articles.latimes.com/2013/may/02/science/la-sci-stay-awake-drug-modafinil-booming-20130502. 
  124. ↑ "The prevalence and cost of unapproved uses of top-selling orphan drugs". PLOS ONE 7 (2): e31894. February 21, 2012. doi:10.1371/journal.pone.0031894. PMID 22363762. Bibcode: 2012PLoSO...731894K. 
  125. ↑ "Cephalon gets six-month Provigil patent extension". Philadelphia Business Journal. March 28, 2006. http://www.bizjournals.com/philadelphia/stories/2006/03/27/daily13.html. 
  126. ↑ "Details for Patent: RE37516". http://www.drugpatentwatch.com/ultimate/preview/patent/index.php?query=RE37516. 
  127. ↑ "Prescription Access Litigation (PAL) Project :: Prescription Access Litigation (PAL) Project :: Lawsuits & Settlements :: Current Lawsuits". Prescriptionaccess.org. http://www.prescriptionaccess.org/lawsuitssettlements/current_lawsuits?id=0024. 
  128. ↑ "Document 514 :: APOTEX, INC. v. CEPHALON, INC. et al". Pennsylvania Eastern District Court :: US Federal District Courts Cases :: Justia. October 31, 2010. http://law.justia.com/cases/federal/district-courts/pennsylvania/paedce/2:2006cv02768/205626/514. 
  129. ↑ 129.0 129.1 "Document 513 :: APOTEX, INC. v. CEPHALON, INC. et al". Pennsylvania Eastern District Court :: US Federal District Courts Cases :: Justia. October 31, 2010. http://law.justia.com/cases/federal/district-courts/pennsylvania/paedce/2:2006cv02768/205626/513. 
  130. ↑ "Cephalon Inc., SEC 10K 2008 disclosure". February 23, 2009. pp. 9–10. https://www.sec.gov/Archives/edgar/data/873364/000104746909001690/a2190556z10-k.htm. 
  131. ↑ "CVS, Rite Aid Sue Cephalon Over Generic Provigil". Bloomberg News. August 21, 2009. https://www.bloomberg.com/apps/news?pid=20601103&sid=arNEtMSU7D9s. 
  132. ↑ "Canada IP Year in Review 2008". January 1, 2009. http://www.mondaq.com/article.asp?articleid=71906. 
  133. ↑ "Shire v. Canada". http://reports.fja-cmf.gc.ca/eng/2008/2008fc538/2008fc538.html. 
  134. ↑ "Cephalon Sues Apotex". Zacks.com. August 20, 2010. http://www.zacks.com/stock/news/39048/Cephalon+Sues+Apotex. 
  135. ↑ ""U.S. Federal Trade Commission Clears Teva's Acquisition of Cephalon". Business Wire. October 7, 2011. http://www.thefreelibrary.com/U.S.+Federal+Trade+Commission+Clears+Teva's+Acquisition+of+Cephalon.-a0268983036. "Teva will also grant non-exclusive U.S. rights to an undisclosed company to market modafinil tablets, the generic version of Provigil(R), which had annual brand sales in the U.S. of approximately $1.1 billion" 
  136. ↑ "Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals". Press Release. PRNewswire. October 18, 2011. http://www.prnewswire.com/news-releases/par-pharmaceutical-acquires-three-generic-products-from-teva-pharmaceuticals-132044783.html. 
  137. ↑ "Cephalon Loses U.K. Bid to Halt Mylan, Orchid Generic-Drug Sales". bloomberg LP. November 19, 2010. https://www.bloomberg.com/news/2010-11-19/cephalon-loses-u-k-bid-to-halt-mylan-orchid-generic-drug-sales.html. 
  138. ↑ "Modafinil – International Brands". Drugs.com. https://www.drugs.com/international/modafinil.html. 
  139. ↑ "Poisons Standard March 2018". Legislation.gov.au. https://www.legislation.gov.au/Details/F2018L00168. 
  140. ↑ "Regulations Amending the Food and Drug Regulations (1184 — Modafinil)". Canada Gazette 140 (20). March 26, 2005. http://gazette.gc.ca/archives/p1/2005/2005-03-26/html/reg5-eng.html#REF1. 
  141. ↑ "食品药品监管总局 公安部 国家卫生计生委关于公布麻醉药品和精神药品品种目录的通知". China Food and Drug Administration. http://samr.cfda.gov.cn/WS01/CL0844/94735.html. 
  142. ↑ "处方管理办法（原卫生部令第53号）" (in zh). http://www.gov.cn/flfg/2007-03/13/content_549406.htm. 
  143. ↑ "莫达非尼国内获批上市 威尔曼新药拥有量再上台阶" (in zh). December 18, 2017. http://hn.people.com.cn/n2/2017/1218/c374564-3. [yes|permanent dead link|dead link}}]
  144. ↑ "List of psychotropics". http://www.ncd.mhlw.go.jp/img/en/total.pdf. 
  145. ↑ "モダフィニルの向精神薬への指定". http://www.fukushihoken.metro.tokyo.jp/kenkou/iyaku/sonota/shitei_m/moda.html. 
  146. ↑ "医疗用医薬品の添付文书情报-モディオダール锭１００ｍｇ" (in ja). http://www.info.pmda.go.jp/go/pack/1179047F1022_2_15/. 
  147. ↑ "モダフィニル密輸で逮捕された歯科医師，ダイエットに使用と供述（報道）". https://medicallaw.exblog.jp/20422896/. 
  148. ↑ "向精神薬をインドから密輸入した男を逮捕". https://hayabusa3.5ch.net/test/read.cgi/news/1391949369/. 
  149. ↑ "AGENȚIA NAȚIONALĂ ANTI-DOPING". http://anad.gov.ro/web/wp-content/uploads/2017/10/LISTA-2018-web.pdf. 
  150. ↑ "LEGE 219 26/07/2021 - Portal Legislativ". https://legislatie.just.ro/Public/DetaliiDocumentAfis/245003. 
  151. ↑ "Data" (PDF). http://base.consultant.ru/cons/cgi/online.cgi?req=doc;base=LAW;n=142882;fld=134;dst=4294967295;rnd=0.8965571122244;from=141820-563. 
  152. ↑ "Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika". https://lakemedelsverket.se/upload/lvfs/konsoliderade/LVFS_2011_10_konsoliderad_tom_HSLF-FS_2019_7.pdf. 
  153. ↑ "Is It Illegal to Obtain Controlled Substances From the Internet?". United States Drug Enforcement Administration. http://www.usdoj.gov/dea/illegal_internet.html. 
  154. ↑ U.S. Justice Department (January 27, 1999). "Schedules of Controlled Substances: Placement of Modafinil Into Schedule IV". Federal Register: The Daily Journal of the United States Government. 64 FR 4050. https://www.federalregister.gov/documents/1999/01/27/99-1791/schedules-of-controlled-substances-placement-of-modafinil-into-schedule-iv. "A Rule by the Justice Department on 01/27/1999". 
  155. ↑ "USC 201 Section 1301.26 Exemptions from import or export requirements for personal medical use". United States Department of Justice. March 24, 1997. http://www.deadiversion.usdoj.gov/21cfr/cfr/1301/1301_26.htm. 
  156. ↑ "Prescription Drug Marketing Act of 1987 (PDMA), PL 100-293". U.S. Food and Drug Administration. https://www.fda.gov/opacom/laws/pdma.html. 
  157. ↑ "Letter to Cephalon 01/03/2002". January 3, 2002. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM164556.pdfFDA. 
  158. ↑ "Class Action Over Cephalon Off-Label Claims Tossed" (in en). Law360. October 9, 2009. https://www.law360.com/articles/127434. "Cephalon executives have repeatedly said that they do not condone off-label use of Provigil, but in 2002 the company was reprimanded by the FDA for distributing marketing materials that presented the drug as a remedy for tiredness, "decreased activity" and other supposed ailments. In 2008, Cephalon paid $425m and pleaded guilty to a federal criminal charge relating to its promotion of off-label uses for Provigil and two other drugs." 
  159. ↑ "Cephalon settlement requires physician payments to be disclosed". Fierce Healthcare. September 30, 2008. http://www.fiercehealthcare.com/story/cephalon-settlement-requires-physician-payments-be-disclosed/2008-09-30. 
  160. ↑ "Lääkealan turvallisuus- ja kehittämiskeskuksen päätöslääkeluettelosta". 2009. http://www.finlex.fi/fi/laki/alkup/2009/20091095. 
  161. ↑ "Bekendtgørelse om euforiserende stoffer" (in da). June 23, 2020. https://www.retsinformation.dk/eli/lta/2020/950. 
  162. ↑ "Estupefacientes y Psicotrópicos" (in es). Federal Commission for Protection against Health Risks. http://www.cofepris.gob.mx/pyp/estpsic/es.htm. 
  163. ↑ SA Government (April 10, 2003). "GENERAL REGULATIONS MADE IN TERMS OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965, AS AMENDED Government Notice R510 in Government Gazette 24727 dated 10 April 2003. 22A/16/b; states that although import and export is restricted, possession is not illegal providing that a prescription is present.". Pretoria: SAFLII. http://www.saflii.org/za/legis/consol_reg/marsa101o1965rangnr510723.pdf. 
  164. ↑ MHRA (April 3, 2013). "MHRA license for Modafinil in UK". London: MHRA. http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con273748.pdf. 
  165. ↑ World Anti-Doping Agency (September 5, 2017). "Prohibited List 2018" (in en). The World Anti-Doping Code: International Standard. https://www.wada-ama.org/sites/default/files/prohibited_list_2018_en.pdf. 
  166. ↑ "Clinger given lifetime ban for second doping infraction". Cycling News. August 14, 2011. http://www.cyclingnews.com/news/clinger-given-lifetime-ban-for-second-doping-infraction. 
  167. ↑ "Taurasi tested positive for modafinil". The Washington Post. December 25, 2010. https://www.washingtonpost.com/wp-dyn/content/article/2010/12/24/AR2010122402993.html. 
  168. ↑ Guardian Sport (November 23, 2015). "British rowers handed two-year bans for taking banned substances". The Guardian. https://www.theguardian.com/sport/2015/nov/23/british-rowers-handed-two-year-bans-doping-violations-sybren-hoogland-timothy-grant. 
  169. ↑ "Taurasi: 'I've lost 3 months of my career'". February 18, 2011. http://sports.espn.go.com/wnba/columns/story?columnist=voepel_mechelle&id=6135920. 
  170. ↑ "Bonds Exposed". Sports Illustrated. March 7, 2006. http://sportsillustrated.cnn.com/2006/baseball/mlb/03/06/news.excerpt/1.html. Retrieved July 2, 2011. 
  171. ↑ "Effects of acute modafinil ingestion on exercise time to exhaustion". Medicine and Science in Sports and Exercise 36 (6): 1078–1082. June 2004. doi:10.1249/01.MSS.0000128146.12004.4F. PMID 15179180. 
  172. ↑ 172.0 172.1 "Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression". CNS Drugs 27 (Suppl 1): S21–S27. May 2013. doi:10.1007/s40263-012-0030-1. PMID 23712796. 
  173. ↑ 173.0 173.1 "Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials". The Journal of Clinical Psychiatry 74 (11): 1101–1107. November 2013. doi:10.4088/JCP.13r08560. PMID 24330897. 
  174. ↑ 174.0 174.1 "Psychostimulants in moderate to severe affective disorder: a systematic review of randomized controlled trials". Nordic Journal of Psychiatry 67 (6): 369–382. December 2013. doi:10.3109/08039488.2012.752035. PMID 23293898. 
  175. ↑ 175.0 175.1 175.2 "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". The Journal of Clinical Psychiatry 75 (9): 1010–1018. September 2014. doi:10.4088/JCP.13r08851. PMID 25295426. 
  176. ↑ 176.0 176.1 "Stimulants for depression: On the up and up?". The Australian and New Zealand Journal of Psychiatry 50 (3): 203–207. March 2016. doi:10.1177/0004867416634208. PMID 26906078. 
  177. ↑ "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". European Neuropsychopharmacology 27 (5): 423–441. May 2017. doi:10.1016/j.euroneuro.2017.03.003. PMID 28318897. 
  178. ↑ 178.0 178.1 "The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology 37 (4): 412–418. August 2017. doi:10.1097/JCP.0000000000000723. PMID 28590365. 
  179. ↑ 179.0 179.1 179.2 179.3 179.4 "Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis". Journal of Affective Disorders 292: 416–423. September 2021. doi:10.1016/j.jad.2021.05.119. PMID 34144366. 
  180. ↑ 180.0 180.1 "A review of the use of modafinil for attention-deficit hyperactivity disorder". Expert Review of Neurotherapeutics 6 (4): 455–468. April 2006. doi:10.1586/14737175.6.4.455. PMID 16623645. 
  181. ↑ "Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis". Journal of Psychiatric Research 84: 292–300. January 2017. doi:10.1016/j.jpsychires.2016.09.034. PMID 27810669. 
  182. ↑ 182.0 182.1 182.2 "A systematic review of modafinil: Potential clinical uses and mechanisms of action". The Journal of Clinical Psychiatry 67 (4): 554–566. April 2006. doi:10.4088/jcp.v67n0406. PMID 16669720. http://pdfs.semanticscholar.org/227a/c1127322026353e2c1b61eabf23b2d0b9040.pdf. 
  183. ↑ "Use of modafinil for the treatment of attention deficit/hyperactivity disorder". The Annals of Pharmacotherapy 40 (10): 1829–1833. October 2006. doi:10.1345/aph.1H024. PMID 16954326. 
  184. ↑ "Alternative pharmacological strategies for adult ADHD treatment: a systematic review". Expert Review of Neurotherapeutics 16 (2): 131–144. 2016. doi:10.1586/14737175.2016.1135735. PMID 26693882. 
  185. ↑ 185.0 185.1 "Updated European Consensus Statement on diagnosis and treatment of adult ADHD". European Psychiatry 56: 14–34. February 2019. doi:10.1016/j.eurpsy.2018.11.001. PMID 30453134. 
  186. ↑ "Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies". Current Drug Abuse Reviews 1 (2): 213–221. June 2008. doi:10.2174/1874473710801020213. PMID 19630720. 
  187. ↑ "Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?". Frontiers in Neuroscience 15: 656475. 2021. doi:10.3389/fnins.2021.656475. PMID 34121988. 
  188. ↑ "Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study". The Journal of Clinical Psychiatry 71 (11): 1475–1481. November 2010. doi:10.4088/jcp.09m05950gry. PMID 20816042. 
  189. ↑ 189.0 189.1 "Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials". Journal of Psychiatric Research 60: 14–21. January 2015. doi:10.1016/j.jpsychires.2014.09.013. PMID 25306261. https://espace.library.uq.edu.au/view/UQ:345290/UQ345290_OA.pdf. 
  190. ↑ "Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence". JAMA Psychiatry 74 (7): 675–684. July 2017. doi:10.1001/jamapsychiatry.2017.0624. PMID 28514486. 
  191. ↑ "How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine". European Neuropsychopharmacology 38: 40–62. September 2020. doi:10.1016/j.euroneuro.2020.07.002. PMID 32709551. https://researchonline.ljmu.ac.uk/id/eprint/13268/8/How%20effective%20are%20pharmaceuticals%20for%20cognitive%20enhancement%20in%20healthy%20adults%20A%20series%20of%20meta-analyses%20of%20cognitive%20performance%20during%20acute%20administration%20of%20modafinil%2C%20methylphenidate%20and%20d-amphetamine..pdf. 
  192. ↑ "The use of psychostimulants in cancer patients". Current Opinion in Supportive and Palliative Care 5 (2): 164–168. June 2011. doi:10.1097/SPC.0b013e3283462ff3. PMID 21532350. 
  193. ↑ "Pharmacological treatments for fatigue associated with palliative care". The Cochrane Database of Systematic Reviews 30 (5): CD006788. May 2015. doi:10.1002/14651858.CD006788.pub3. PMID 26026155. 
  194. ↑ "Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study". Neurology 65 (12): 1995–1997. December 2005. doi:10.1212/01.wnl.0000200985.04239.53. PMID 16380634. 
  195. ↑ "Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial". The Lancet. Neurology 20 (1): 38–48. January 2021. doi:10.1016/S1474-4422(20)30354-9. PMID 33242419. 

External Links



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Modafinil&oldid=3196975"